Literature DB >> 15741200

Pathogenesis of Raynaud's phenomenon.

A L Herrick1.   

Abstract

The pathogenesis of Raynaud's phenomenon is not fully understood. However, the last 20 yr have witnessed enormous increases in our understanding of different mechanisms which, singly or in combination, may contribute. A key point is that Raynaud's phenomenon can be either primary (idiopathic) or secondary to a number of underlying conditions, and that the pathogenesis and pathophysiology vary between these conditions. This review concentrates upon those subtypes of Raynaud's phenomenon of most interest to rheumatologists: systemic sclerosis-related Raynaud's phenomenon, primary Raynaud's phenomenon and Raynaud's phenomenon secondary to hand-arm vibration syndrome. In this review, I shall discuss the main mechanisms thought to be important in pathophysiology under the three broad headings of 'vascular', 'neural' and 'intravascular'. While these are false distinctions because all interrelate, they facilitate discussion of the key elements: the blood vessel wall (particularly the endothelium), the neural control of vascular tone, and the many circulating factors which can impair blood flow and/or cause endothelial injury. Vascular abnormalities include those of both structure and function. Neural abnormalities include deficiency of the vasodilator calcitonin gene-related peptide (released from sensory afferents), alpha(2)-adrenoreceptor activation (possibly with up-regulation of the normally 'silent' alpha(2C)-adrenoreceptor) and a central nervous system component. Intravascular abnormalities include platelet activation, impaired fibrinolysis, increased viscosity and probably oxidant stress. As our understanding of the pathophysiology of Raynaud's phenomenon increases, so do our possibilities for identifying effective treatments.

Entities:  

Mesh:

Year:  2005        PMID: 15741200     DOI: 10.1093/rheumatology/keh552

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  87 in total

1.  Association of von Willebrand factor and fibrinogen plasma levels with primary Raynaud's phenomenon in male and female patients.

Authors:  Alajos-Tamas Takáts; Amir-Houshang Shemirani; Katalin-Szilvia Zsóri; Csilla András; Zoltán Csiki
Journal:  Rheumatol Int       Date:  2011-11-16       Impact factor: 2.631

Review 2.  The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors:  Ariane L Herrick
Journal:  Nat Rev Rheumatol       Date:  2012-07-10       Impact factor: 20.543

Review 3.  Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.

Authors:  Maria Trojanowska
Journal:  Nat Rev Rheumatol       Date:  2010-06-29       Impact factor: 20.543

Review 4.  [Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

5.  Citalopram-induced Raynaud's phenomenon.

Authors:  A M Peiró; C Margarit; M Torra
Journal:  Rheumatol Int       Date:  2006-11-14       Impact factor: 2.631

6.  Successful treatment with bosentan for severe digital ischaemia in limited cutaneous systemic sclerosis.

Authors:  Emma P K Yu; Andrew J K Ostor; Frances C Hall
Journal:  Ann Rheum Dis       Date:  2007-08       Impact factor: 19.103

7.  Raynaud's phenomenon.

Authors:  Ariane Herrick
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-04

8.  Raynaud's phenomenon and vitamin D.

Authors:  Josiane Hélou; Roy Moutran; Ismael Maatouk; Fady Haddad
Journal:  Rheumatol Int       Date:  2012-05-12       Impact factor: 2.631

9.  Nailfold capillaroscopy assessment of microcirculation abnormalities and endothelial dysfunction in children with primary or secondary Raynaud syndrome.

Authors:  Joanna Latuskiewicz-Potemska; Antonina Chmura-Skirlinska; Ryszard J Gurbiel; Elzbieta Smolewska
Journal:  Clin Rheumatol       Date:  2016-06-29       Impact factor: 2.980

Review 10.  Raynaud's phenomenon (secondary).

Authors:  Ariane Herrick
Journal:  BMJ Clin Evid       Date:  2008-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.